Skip to main content

Intal Inhaler Disease Interactions

There is 1 disease interaction with Intal Inhaler (cromolyn).

Minor

Cromolyn (applies to Intal Inhaler) renal/liver disease

Minor Potential Hazard, Low plausibility. Applicable conditions: Renal Dysfunction

Systemically absorbed cromolyn is eliminated almost equally by renal and biliary routes. Although less than 1% of an orally ingested dose and approximately 8% of an orally inhaled dose is systemically available, the manufacturers recommend that a dosage reduction be considered in patients with impaired renal or hepatic function.

References (7)
  1. Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST (1987) "Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique." J Pharmacol Exp Ther, 241, p. 1028-32
  2. Rosenberg JL, Edlow D, Sneider R (1978) "Liver disease and vasculitis in a patient taking cromolyn." Arch Intern Med, 138, p. 989-91
  3. Neale MG, Brown K, Hodder RW, Auty RM (1986) "The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration." Br J Clin Pharmacol, 22, p. 373-82
  4. Fuller RW, Collier JG (1983) "The pharmacokinetic assessment of sodium cromoglycate." J Pharm Pharmacol, 35, p. 289-92
  5. Walker SR, Evans ME, Richards AJ, Paterson JW (1972) "The fate of [14C]disodium cromoglycate in man." J Pharm Pharmacol, 24, p. 525-31
  6. (2001) "Product Information. Intal (cromolyn)." Rhone Poulenc Rorer
  7. (2001) "Product Information. Gastrocrom (cromolyn)." Rhone Poulenc Rorer

Switch to consumer interaction data

Intal Inhaler drug interactions

There is 1 drug interaction with Intal Inhaler (cromolyn).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer